Your comment is laughable.
There have been hundreds of clinical trials based on science that have failed.
I try to talk to people who have wide experience with a range of retina drugs -- in other words, the docs.
I have always made changes around year-end.
I believe that tax selling plays a huge role in creating undervalued stocks (bargains).
So some things go and new ones replace them.
I have already seen some laggards reversing -- like AKS and ARAY.
I expect to see more stocks reverse to the upside in the next two weeks -- maybe MOS and RIG for two.
I think Livermore has made an error in attempting to dominate the board -- he doesn't consider arguments that go against his own/. I don't think "volume" posting wins the argument.
I have other fish to fry that seem to be more dependable in terms of a positive investment outcome -- ARAY for one, which has the CyberKnife and an installed base of 700+ radiation therapy units worldwide. ARAY has a growing backlog and stock seems under accumulation.So maybe I am just culling the herd.
Also, possible year-end bargains in some beaten-down stocks like MOS and RIG.
Sometimes you have to prioritize. I consider year-end an important point for redoing a portfolio of common stocks. One year's laggards can become next year's leaders.
In my experience, stocks tend to move up in advance of the good news being announced. I recently saw that in MAKO right before the takeover was announced. I may be seeing it now in ARAY, as I think this is also a takeover candidate.Stocks tend to drop in advance of bad news being announced -- happens all the time.
It is just my impression that OHRP shares would be acting differently if it was demonstrating great efficacy.
Squalamine has a long history of failure. Might work for maintenance, which would still be huge.
There would be more leaks. That's just the way the world works. (Spare me more Dr. K newsletter stuff) The trial has been on for awhile now and somebody must know something. The stock just doesn't act like a success story would in the early stages of investors recognizing a good thing.
I have no knowledge of anything but I still stick with my belief that this is a WEAK antiangiogenic. There are hundreds of weak antiangiogenics in nature and Magainin chose this one to take a chance on years ago. The history of squalamine in clinical trials for several indications is not that great. Could be a "fooler."
I have said it before but I still believe that there are about 20 people in the country who have an idea about how all of this will shake out -- and none of those people are contributors to this board. If squalamine was really doing all that great in the trial, wouldn't there have been many leaks? The fact that there has been one leak only is not that positive in my opinion. And where was the one leak? In a practice newsletter -- a marketing tool.
There's a saying in poker that if you don't know who the pigeon is at the table, it's probably you.
This is not the type of article covered by Ophthalmology Management.
Must be a mistake.
Ophthalmology Management is not into deep clinical topics.
"And you should too" ??
I am for whatever works best -- that might be squalamine and then again, it might be something else.
It was published in a practice newsletter, which is just a marketing tool.
At best, it's anecdotal.
I would take it in that context and not as clinical proof of efficacy.
I believe squalamine was studied for lung cancer -- which is a very tough disease to treat.
Squalamine was too weak to be effective -- squalamine has proved over and over that it is a weak antiangiogenic.
They should just stick with the ere indication and hope it is effective enough to serve as maintenance therapy.
Livermore always paints the best-case scenario for OHRP and the worst-case for every other company in the arena.
Reality is seldom like that.
The Reuters article has not created a groundswell of interest in buying OHRP shares.
I would have expected more activity this am.
PVA is already profitable on a non-GAAP basis.
Analysts scrambling like lemmings now to raise their target price for PVA.
Guys who were at 4 are now at 12 target
Analysts are a joke for the most part.
I was never a fan of Ophthotech -- from the folks who brought you Macugen.
I am more impressed by Allegro's Integrin Peptide Therapy (in combination with anti-VEGF)
REGN and Genentech also moving ahead with combos formulated in a single injection.
Ophthotech requires two injections.
Retina docs are the creme de la creme of ophthalmology.
Plus, they are first and foremost surgeons.
They don't fit very well in outpatient surgery centers because they can't do eight cases an hour.
They might spend 90 minutes on one patient because retinal surgery is complex -- it's not cataracts.
This will have to be one heckuva eye drop to get them to prescribe it as first line.
This would go against all of their instincts and training.